基本信息
views: 6
Career Trajectory
Bio
My research focus on four streams of work, vaccine policy research, the development of novel methodological tools, integration of serological data into models to understand transmission and real-time modelling and outbreak response. I have also 10 years of experience working in a public health institution (Public Health England).
Real-time modelling and outbreak response I have a keen interest in the particular problem of real-time modelling for outbreak response. This includes understanding the sources of uncertainties and including these in the inference methods, and designing fast and efficient models to inform policy makers. As part of the modelling team for PHE (then HPA), I built in real-time the model that informed the UK Scientific Advisory Group for Emergencies and the JCVI on vaccination strategy during the 2009 pandemic in the UK and was part of the modelling taskforce at the London School of Hygiene and Tropical Medicine during the 2014 Ebola crisis in West Africa. I am now fully committed to provide modelling support for the COVID-19 outbreak response.
Vaccine policy research I developed transmission models and cost-effectiveness analyses to support policy makers in decisions regarding changes to immunization programmes. For the last 10 years, I have been a regular contributor to the Joint Committee on Vaccination and Immunisation in the UK. In particular I have developed models and undertaken the cost-effectiveness analyses supporting the vaccination of pregnant women against seasonal influenza, the introduction of paediatric influenza vaccination in children, quadrivalent influenza vaccines and assessing the impact of the new paediatric arm of the flu immunisation programme on the pre-existing elderly arm. I have also lead studies on the cost-effectiveness of influenza and high dose influenza vaccines.
Development of novel methodological tools I am driven to improve existing methodological tools whenever possible in particular to fully exploit new data streams. In the past years I have developed with various academic collaborators novel methods to improve the inference of transmission model parameters using surveillance data. With collaborators at the London School of Economics I have developed a method to include a diffusion process to represent time varying quantities when mechanisms of change are difficult to assess, co-developed two R packages, one for handling jointly genetic and epidemiological information, and the second for performing evidence synthesis and cost-effectiveness from influenza surveillance data.
Integration of serological data into models to understand transmission As a result of my interactions with epidemiologists and virologists, I have developed a strong interest in using biological markers (in particular antibody titres from sera) to better understand pathogens transmission. I have developed a framework to derive infection incidence from sequential serology while integrating potential additional data sources, a new type of model including the dynamics of titre changes alongside the dynamics of transmission. During the 2014 Ebola crisis in West Africa, I have developed a household serological survey in the Democratic Republic of Congo to assess asymptomatic transmission. The resulting data were analysed using a Bayesian mixture model. The protocol was then adapted to survey returning healthcare workers, estimate potential asymptomatic infection rate and link it with risk while in the field.
Real-time modelling and outbreak response I have a keen interest in the particular problem of real-time modelling for outbreak response. This includes understanding the sources of uncertainties and including these in the inference methods, and designing fast and efficient models to inform policy makers. As part of the modelling team for PHE (then HPA), I built in real-time the model that informed the UK Scientific Advisory Group for Emergencies and the JCVI on vaccination strategy during the 2009 pandemic in the UK and was part of the modelling taskforce at the London School of Hygiene and Tropical Medicine during the 2014 Ebola crisis in West Africa. I am now fully committed to provide modelling support for the COVID-19 outbreak response.
Vaccine policy research I developed transmission models and cost-effectiveness analyses to support policy makers in decisions regarding changes to immunization programmes. For the last 10 years, I have been a regular contributor to the Joint Committee on Vaccination and Immunisation in the UK. In particular I have developed models and undertaken the cost-effectiveness analyses supporting the vaccination of pregnant women against seasonal influenza, the introduction of paediatric influenza vaccination in children, quadrivalent influenza vaccines and assessing the impact of the new paediatric arm of the flu immunisation programme on the pre-existing elderly arm. I have also lead studies on the cost-effectiveness of influenza and high dose influenza vaccines.
Development of novel methodological tools I am driven to improve existing methodological tools whenever possible in particular to fully exploit new data streams. In the past years I have developed with various academic collaborators novel methods to improve the inference of transmission model parameters using surveillance data. With collaborators at the London School of Economics I have developed a method to include a diffusion process to represent time varying quantities when mechanisms of change are difficult to assess, co-developed two R packages, one for handling jointly genetic and epidemiological information, and the second for performing evidence synthesis and cost-effectiveness from influenza surveillance data.
Integration of serological data into models to understand transmission As a result of my interactions with epidemiologists and virologists, I have developed a strong interest in using biological markers (in particular antibody titres from sera) to better understand pathogens transmission. I have developed a framework to derive infection incidence from sequential serology while integrating potential additional data sources, a new type of model including the dynamics of titre changes alongside the dynamics of transmission. During the 2014 Ebola crisis in West Africa, I have developed a household serological survey in the Democratic Republic of Congo to assess asymptomatic transmission. The resulting data were analysed using a Bayesian mixture model. The protocol was then adapted to survey returning healthcare workers, estimate potential asymptomatic infection rate and link it with risk while in the field.
Research Interests
Papers共 143 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Wellcome Open Research (2024)
Cited0Views0Bibtex
0
0
Harrison Manley, Thomas Bayley, Gabriel Danelian,Lucy Burton,Thomas Finnie,Andre Charlett,Nicholas A Watkins,Paul Birrell,Daniela De Angelis,Matt Keeling,Sebastian Funk,Graham Medley,
Royal Society open scienceno. 5 (2024): 231832-231832
Marta C. Nunes,Edward Thommes,Holger Froehlich,Antoine Flahault,Julien Arino,Marc Baguelin,Matthew Biggerstaff, Gaston Bizel-Bizellot,Rebecca Borchering, Giacomo Cacciapaglia,Simon Cauchemez,Alex Barbier-Chebbah,
INFECTIOUS DISEASE MODELLINGno. 2 (2024): 501-518
Su Myat Han,Teiichiro Shiino,Shingo Masuda,Yuki Furuse,Takahiro Yasaka,Satoshi Kanda, Kazuhiri Komori,Nobuo Saito, Yoshiano Kubo,Chris Smith,Akira Endo,Alexis Robert,
medrxiv(2024)
Wellcome open research (2024): 12-12
The Lancet. Public healthno. 3 (2023): e174-e183
crossref(2023)
Nature Communicationsno. 1 (2023): 1-4
SSRN Electronic Journalno. 1 (2023): 1-12
Load More
Author Statistics
#Papers: 143
#Citation: 9987
H-Index: 37
G-Index: 99
Sociability: 7
Diversity: 0
Activity: 2
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn